Clearmind Medicine has been granted divisional patent approval by the China National Intellectual Property Administration. The granting of this latest patent establishes both the company’s patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space. Clearmind’s IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted patents in major jurisdictions such as the US, Europe, China, and India.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CMND:
- Rising High: Exclusive talk with drug manufacturer Optimi Health
- Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
- Clearmind Medicine enter long-term licensing agreement with BIRAD
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Clearmind Medicine closes $2.4M registered direct, private placement